Microcalcification and 99mTc-Pyrophosphate Uptake without Increased Bone Metabolism in Cardiac Tissue from Patients with Transthyretin Cardiac Amyloidosis. 2023

Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.

Transthyretin cardiac amyloidosis (ATTR-CA) is characterized by high 99mTc-labeled bone tracer uptake in the heart. However, the mechanism of bone tracer uptake into the heart remains controversial. Since bone tracer uptake into metastatic bone tumors is thought to be associated with increased bone metabolism, we examined 99mTc-pyrophosphate (PYP) scintigraphy findings, endomyocardial biopsy (EMB) tissue findings, and the expression of bone metabolism-related genes in the EMB tissues in patients with ATTR-CA, amyloid light-chain cardiac amyloidosis (AL-CA), and noncardiac amyloidosis (non-CA) in this study. The uptake of 99mTc-PYP in the heart was significantly higher in the ATTR-CA patients than in the AL-CA and non-CA patients. A higher percentage of ATTR-CA EMB tissue showed von Kossa-positive microparticles: ATTR-CA, 62%; AL-CA, 33%; and non-CA, 0%. Calcified microparticles were identified using transmission electron microscopy. However, none of the osteogenic marker genes, osteoclastic marker genes, or phosphate/pyrophosphate-related genes were upregulated in the EMB samples from ATTR-CA patients compared to those from AL-CA and non-CA patients. These results suggest that active calcification-promoting mechanisms are not involved in the microcalcification observed in the heart in ATTR-CA. The mechanisms explaining bone tracer uptake in the heart, which is stronger than that in the ribs, require further investigation.

UI MeSH Term Description Entries
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D011228 Prealbumin A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease. Proalbumin,Transthyretin
D011756 Diphosphates Inorganic salts of phosphoric acid that contain two phosphate groups. Diphosphate,Pyrophosphate Analog,Pyrophosphates,Pyrophosphate Analogs,Analog, Pyrophosphate
D002114 Calcinosis Pathologic deposition of calcium salts in tissues. Calcification, Pathologic,Calcinosis, Tumoral,Microcalcification,Microcalcinosis,Pathologic Calcification,Calcinoses,Calcinoses, Tumoral,Microcalcifications,Microcalcinoses,Tumoral Calcinoses,Tumoral Calcinosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075363 Immunoglobulin Light-chain Amyloidosis A nonproliferative disorder of PLASMA CELLS characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies. Monoclonal Immunoglobulin Deposition Disease,AL Amyloidosis,Amyloidosis, Immunoglobulin Light-chain,Amyloidosis, Primary,Primary Amyloidosis,Primary Systemic Amyloidosis,AL Amyloidoses,Amyloidoses, Primary,Amyloidoses, Primary Systemic,Amyloidosis, Immunoglobulin Light chain,Amyloidosis, Primary Systemic,Immunoglobulin Light chain Amyloidosis,Immunoglobulin Light-chain Amyloidoses,Primary Amyloidoses,Primary Systemic Amyloidoses,Systemic Amyloidoses, Primary,Systemic Amyloidosis, Primary
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D019275 Radiopharmaceuticals Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) Radiopharmaceutical

Related Publications

Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
February 2020, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
September 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
January 1990, European journal of nuclear medicine,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
January 2023, Clinical nuclear medicine,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
October 2019, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
December 2022, JACC. Cardiovascular imaging,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
February 2024, European heart journal. Cardiovascular Imaging,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
October 2021, Clinical nuclear medicine,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
October 2023, European journal of nuclear medicine and molecular imaging,
Atsushi Mori, and Yukihiro Saito, and Kazufumi Nakamura, and Toshihiro Iida, and Satoshi Akagi, and Masashi Yoshida, and Makiko Taniyama, and Toru Miyoshi, and Hiroshi Ito
August 2018, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Copied contents to your clipboard!